A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification

被引:81
作者
Chefetz, I
Heller, R
Galli-Tsinopoulou, A
Richard, G
Wollnik, B
Indelman, M
Koerber, F
Topaz, O
Bergman, R
Sprecher, E [1 ]
Schoenau, E
机构
[1] Rambam Med Ctr, Dept Dermatol, Lab Mol Dermatol, IL-9602 Haifa, Israel
[2] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[3] Univ Cologne, Inst Human Genet, Cologne, Germany
[4] Univ Cologne, CMMC, Cologne, Germany
[5] Univ Thessaloniki, Hop Papageorgiu, Dept Pediat 4, GR-54006 Thessaloniki, Greece
[6] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA
[7] Univ Cologne, Childrens Hosp, Dept Pediat Radiol, Cologne, Germany
[8] Univ Cologne, Childrens Hosp, Dept Pediat Endocrinol, Cologne, Germany
关键词
calcinosis; FGF23; GALNT3; phosphate; mutation; extraskeletal;
D O I
10.1007/s00439-005-0026-8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hyperphosphatemic Familial Tumoral Calcinosis (HFTC; MIM211900) is a rare autosomal recessive disorder characterized by the progressive deposition of calcified masses in cutaneous and subcutaneous tissues, associated with elevated circulating levels of phosphate. The disease was initially found to result from mutations in GALNT3 encoding a glycosyltransferase. However, more recently, the S71G missense mutation in FGF23, encoding a potent phosphaturic protein, was identified in two families. In the present report, we describe a second mutation in FGF23 underlying a severe case displaying calcifications of cutaneous and numerous extracutaneous tissues. The mutation (M96T) was found to affect a highly conserved methionine residue at position 96 of the protein. These observations illustrate the extent of genetic and phenotypic heterogeneity in HFTC.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 21 条
[1]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[2]   Molecular pathogenesis of hypophosphatemic rickets [J].
de Beur, SMJ ;
Levine, MA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (06) :2467-2473
[3]   Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders [J].
Frishberg, Y ;
Topaz, O ;
Bergman, R ;
Behar, D ;
Fisher, D ;
Gordon, D ;
Richard, G ;
Sprecher, E .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2005, 83 (01) :33-38
[4]  
GIARD A, 1898, CR SOC BIOL, V10, P1015
[5]   A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis:: Evidence that the disorder is autosomal recessive [J].
Ichikawa, S ;
Lyles, KW ;
Econs, MJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :2420-2423
[6]   A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis [J].
Larsson, T ;
Yu, XJ ;
Davis, SI ;
Draman, MS ;
Mooney, SD ;
Cullen, MJ ;
White, KE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :2424-2427
[7]  
MCCLATCHIE S, 1969, BMJ-BRIT MED J, V1, P153
[8]   TUMORAL CALCINOSIS REVISITED - COMMON AND UNCOMMON FEATURES - REPORT OF 10 CASES AND REVIEW [J].
METZKER, A ;
EISENSTEIN, B ;
OREN, J ;
SAMUEL, R .
EUROPEAN JOURNAL OF PEDIATRICS, 1988, 147 (02) :128-132
[9]   Bone densities and bone size at the distal radius in healthy children and adolescents: A study using peripheral quantitative computed tomography [J].
Neu, CM ;
Manz, F ;
Rauch, F ;
Merkel, A ;
Schoenau, E .
BONE, 2001, 28 (02) :227-232
[10]   A case of familial tumoral calcinosis in a neonate and review of the literature [J].
Polykandriotis, EP ;
Beutel, FK ;
Horch, RE ;
Grünert, J .
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2004, 124 (08) :563-567